{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:56Z","timestamp":1792720376823,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006097.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"reference-count":70,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006097.pub3","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T12:47:45Z","timestamp":1533300465000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Natalizumab for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Seana ML","family":"Nelson","sequence":"first","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John WD","family":"McDonald","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"issue":"Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0002|cit1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.62.suppl_2.ii70","article-title":"Alpha4 Integrin blockade in inflammatory bowel disease","volume":"62","author":"Ghosh","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub3-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/S0016-5085(03)81912-1","article-title":"Quality of life improvements in a phase 2 study of natalizumab for active Crohn's disease","volume":"124","author":"Rutgeerts","year":"2003","journal-title":"Gastroenterology"},{"issue":"5 Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0004|cit4","first-page":"A","article-title":"A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to \u03b14 integrin (AntegrenTM) in moderate to severely active Crohn's disease","volume":"120","author":"Letchworth United","year":"2001","journal-title":"Gastroenterology"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD006097.pub3-BIB0005|cit5","first-page":"A726","article-title":"Randomised double blind placebo controlled trial of recombinant humanised antibody to a4 integrin (AntegrenTM) in active Crohn's disease","volume":"116","author":"Gordon","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0006|cit6","first-page":"A42","article-title":"Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha-4 integrin (antegren) in active Crohns disease","volume":"44","author":"Gordon","year":"1999","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD006097.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0008|cit8","first-page":"A576","article-title":"12-Month steroid-sparing results of natalizumab in a controlled study of patients with Crohn\u2019s Disease","volume":"128","author":"Colombel","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0009|cit9","article-title":"Natalizumab provides consistent induction efficacy for patients with moderate to severe Crohn's Disease and elevated C-reactive protein a comparison of ENACT-1 and ENCORE","author":"Colombel","year":"2007","journal-title":"UEGW Abstract Database"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0010|cit10","first-page":"A462","article-title":"Safety, tolerability and immunogenicity of natalizumab in a phase III study of active Crohn's disease therapy (ENACT-1)","volume":"126","author":"Enns","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0011|cit11","first-page":"A","article-title":"Maintenance treatment with natalizumab improves the health related quality of life (HRQOL) in Crohn\u2019s disease patients","volume":"130","author":"Feagan","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0012|cit12","first-page":"S1059","article-title":"The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNF\u00e1 therapy in the ENACT-2 trial","volume":"136","author":"Feagan","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD006097.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1572-0241.2007.01508.x","article-title":"Health-related quality of life during natalizumab maintenance therapy for Crohn's disease","volume":"102","author":"Feagan","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"a Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0014|cit14","first-page":"A213","article-title":"Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn's disease: Results from ENACT-1","volume":"126","author":"Geboes","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0015|cit15","first-page":"A211","article-title":"Pharmacodynamic results from a phase 3 study evaluating natalizumab therapy of active Crohn's disease (ENACT-1)","volume":"126","author":"Lawrance","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0016|cit16","first-page":"A76","article-title":"Comparability of natalizumab pharmacokinetics (PK), alpha-4-integrin receptor saturation and clinical response in patients with Crohn's disease (CD) treated once monthly IV with either a fixed dose of 300 mg (ENACT-1) or doses of 3 or 6 mg\/kg","volume":"126","author":"Panaccione","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0017|cit17","first-page":"A584","article-title":"Efficacy Of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: 12-month results from Enact-2","volume":"128","author":"Panaccione","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00054725-200802001-00033","article-title":"Natalizumab induces and maintains continuous response and remission in patients with active Crohn\u2019s disease despite prior anti-tumor necrosis factor-alpha treatment","volume":"14","author":"Panaccione","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0019|cit19","first-page":"A","article-title":"Natalizumab maintains remission in patients with moderately to severely active Crohn\u2019s disease for up to 2-Years: Results from an open-label extension study","volume":"130","author":"Panaccione","year":"2006","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0020|cit20","first-page":"A208","article-title":"Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1)","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0021|cit21","first-page":"A76","article-title":"Efficacy of assessment of Natalizumab in patients with Crohn's Disease and prior history of anti-TNF therapy: Results from ENACT","volume":"126","author":"Sandborn","journal-title":"2004"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0022|cit22","first-page":"A586","article-title":"Efficacy of natalizumab in maintaining clinical response and remission in Crohn's disease: Comparison of sustained response and remission rates through 12 months Vs point-In-time response and remission rates at month 12","volume":"128","author":"Sandborn","year":"2005","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0023|cit23","first-page":"A","article-title":"Maintenance therapy with natalizumab does not require use of concomitant immunosuppressants for sustained efficacy in patients with active Crohn\u2019s Disease: Results from the ENACT-2 study","volume":"130","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006097.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0025|cit25","article-title":"Immunogenicity of natalizumab in Crohn\u2019s patients following continuous or interrupted dosing","author":"Schreiber","year":"2006","journal-title":"UEGW Abstract Database"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl. 2","key":"10.1002\/14651858.CD006097.pub3-BIB0027|cit27","first-page":"A463","article-title":"Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SGA.0b013e3181bb1484","article-title":"Health-related quality-of-life evaluation of Crohn disease patients after receiving natalizumab therapy","volume":"32","author":"Dudley-Brown","year":"2009","journal-title":"Gastroenterology Nursing"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0029|cit29","article-title":"Natalizumab induction therapy results in improved quality of life in Crohn's disease patients","author":"Feagan","year":"2006","journal-title":"UEGW Abstract Database"},{"issue":"4 Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0030|cit30","first-page":"A","article-title":"Natlizumab does not require the concomitant use of immunosuppressants for the induction of sustained response and remission in Crohn's disease patients","volume":"132","author":"Lashner","year":"2007","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0031|cit31","first-page":"A","article-title":"Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores .330: Results from the ENCORE trial","volume":"132","author":"Panaccione","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0032|cit32","article-title":"Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores 330: Results from the ENCORE trial","author":"Panaccione","year":"2007","journal-title":"UEGW Abstract Database"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"A180","DOI":"10.1016\/S0016-5085(09)60811-8","article-title":"The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNFalpha therapy in the ENCORE trial","volume":"136","author":"Panaccione","year":"2009","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 1","key":"10.1002\/14651858.CD006097.pub3-BIB0034|cit34","first-page":"A 507","article-title":"Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: Results from the Encore trial","volume":"132","author":"Present","year":"2007","journal-title":"Gatsroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0035|cit35","article-title":"Natalizumab induces sustained response and remission in Crohn\u2019s disease patients after previous anti-TNF alpha therapy failure: results from the ENCORE trial","author":"Rutgeerts","year":"2007","journal-title":"UEGW- Abstract Database"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0036|cit36","article-title":"Natalizumab does not require the concomitant use of immunosuppressants for the induction or sustained response and remission in Crohn\u2019s disease patients","author":"Spehlmann","year":"2007","journal-title":"UEGW - Abstract Database"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0037|cit37","article-title":"Natalizumab induces sustained response and remission in patients with active Crohn\u2019s disease: ENCORE trial results","author":"Spehlmann","year":"2006","journal-title":"UEGW Abstract Database"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0038|cit38","first-page":"A587","article-title":"Maintenance therapy with natalizumab (enact-2) for patients with active Crohn\u2019s disease despite immunosuppressant use","volume":"128","author":"Targan","year":"2005","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub3-BIB0039|cit39","first-page":"A108","article-title":"Natalizumab induces sustained response and remission with active Crohn's disease: results from the ENCORE trial","volume":"130","author":"Targan","year":"2006","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"issue":"S1","key":"10.1002\/14651858.CD006097.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/00054725-200802001-00102","article-title":"Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohn\u2019s disease","volume":"14","author":"Wolf","year":"2008","journal-title":"Inflammatory Bowel Disease"},{"issue":"12","key":"10.1002\/14651858.CD006097.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ibd.22943","article-title":"Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience","volume":"18","author":"Kane","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMc055235","article-title":"Natalizumab and progressive multifocal leukoencephalopathy","volume":"353","author":"Adelman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"Alpha4 integrins as therapeutic targets in autoimmune disease","volume":"348","author":"Andrian","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0046|cit46","unstructured":"Biogen TYSABRI\u00ae (natalizumab): PML in patients receiving TYSABRI (USA TYSABRI PML Update) medinfo.biogen.com\/"},{"issue":"20","key":"10.1002\/14651858.CD006097.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006097.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006097.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0050|cit50","first-page":"839-51","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2016","journal-title":"Gut"},{"issue":"15","key":"10.1002\/14651858.CD006097.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.3748\/wjg.v21.i15.4744","article-title":"Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis","volume":"21","author":"Ge","year":"2015","journal-title":"World journal of gastroenterology"},{"issue":"7650","key":"10.1002\/14651858.CD006097.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0054|cit54","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-Demasters","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7400","key":"10.1002\/14651858.CD006097.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006097.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD006097.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1097\/MD.0000000000000556","article-title":"Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006097.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"10.1002\/14651858.CD006097.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006097.pub3-BIB0063|cit63","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"Available from www.cochrane-handbook.org, 2011"},{"issue":"3","key":"10.1002\/14651858.CD006097.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006097.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.suc.2007.03.001","article-title":"Pathophysiology of inflammatory bowel disease: an overview","volume":"87","author":"Thoreson","year":"2007","journal-title":"Surgical Clinics of North America"},{"issue":"2","key":"10.1002\/14651858.CD006097.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3748\/wjg.v18.i2.105","article-title":"Role of genetics in the diagnosis and prognosis of Crohn's disease","volume":"18","author":"Tsianos","year":"2012","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Assche","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006097.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006097.pub3-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097","article-title":"Natalizumab for induction of remission in Crohn's disease","author":"MacDonald","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub3-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097.pub2","article-title":"Natalizumab for induction of remission in Crohn's disease","author":"MacDonald","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006097.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T05:56:08Z","timestamp":1751781368000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006097.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006097.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}